Concepedia

Scott B Yerganian

SB

Statistics

Publications

1

Citations

28

H-Index

1

Active since

2013

Affiliations

Merck (Germany)(Current)

Scott B Yerganian is an author at Merck (Germany) specializing in molecular oncology, tumor biology, and cancer research.

Top concepts

Publications per year

2013–2013

1

Publications

1

Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

Rebecca S. Heist, Leena Gandhi, Geoffrey I. Shapiro et al. · Journal of Clinical Oncology · 2013 · 28 citations

, , +15

1–1 of 1